Related to Ipsen to Pay Inspiration $344M in Funding and Equity Investment as Part of Hemophilia Alliance

• Lentigen and Expression Therapeutics to Develop Hemophilia A Therapies
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication
  
• French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug
  
• Biogen Idec Takes Over Development of Hemophilia Therapies in Deal with Swedish Orphan Biovitrum
  
• Lipoxen Earns $2M from Baxter as Latter Selects PolyXen-Formulated FVIII Candidate
  
• Biogen Idec Restructuring Will Close Sites & Divest Cancer Assets to Save $300M a Year
  
• Baxter Nabs Archemix' Lead Synthetic Hemophilia Candidate and Assets for About $30M
  
• Ipsen Drops Irosustat Monotherapy Program in Cancer but Will Evaluate Combination Therapy Options
  
• Zinc Finger-Based Approach Rectifies Clotting Times in Mice with Hemophilia B
  
• Shire, Sangamo Ink $13M Up-Front Deal for ZFPs against Hemophilia and Monogenic Disorders
  
• Long-Lasting Hemophilia Treatment Succeeds in Phase III
  
• Novo Nordisk Drops Phase III Hemophilia Drug
  
• Bispecific IgG with Benefits Treats Hemophilia A
  
• Firms Project 2013 BLA for Long-Acting Hemophilia A Therapy
  
• Oncodesign and LNGT Enter Research Collaboration with Ipsen for Parkinson's Disease
  
• A Good Day for Milestones
  
• Novo Nordisk Reports Promising Phase III Results for Hemophilia Candidate